Related Experiment Videos
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
R G Miller1, J D Mitchell, M Lyon
1Department of Neurology, California Pacific Medical Center, San Francisco, USA. miller@cooper.cpmc.org
Summary
Riluzole (100 mg) likely extends survival by approximately two months for patients with amyotrophic lateral sclerosis (ALS). While generally safe, its clinical utility is debated due to modest benefits and high cost.
Area of Science:
- Neurology
- Pharmacology
Background:
- Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
- Riluzole is an approved medication for ALS treatment.
- Questions remain regarding riluzole's clinical utility due to cost and modest efficacy.
Purpose of the Study:
- To evaluate the efficacy of riluzole in prolonging survival in ALS patients.
- To assess riluzole's impact on delaying the need for respiratory support (tracheostomy and mechanical ventilation).
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials.
- Searched the Cochrane Neuromuscular Disease Group Register and contacted experts.
- Included adult ALS patients treated with riluzole or placebo, analyzing survival, function, and adverse events.
Main Results:
- Riluzole 100 mg daily showed a modest survival benefit, potentially prolonging life by about two months.
- A significant survival advantage was observed at 6, 9, 12, and 15 months post-treatment.
- Increased alanine transferase levels were more frequent in the riluzole group; minor reversible adverse effects were noted.
Conclusions:
- Riluzole (100 mg daily) is considered reasonably safe and offers a probable survival benefit for ALS patients.
- Further research is recommended to clarify its effects in elderly patients and those with advanced disease stages.